{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-268319","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.409507+00:00","generated_at":"2026-06-09T03:02:16.746072+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"FDA approves Phathom's VOQUEZNA for Erosive GERD; triggers $175M payment","bullets":["FDA approved VOQUEZNA (vonoprazan) for healing, maintenance, and heartburn relief in Erosive GERD.","Phase 3 PHALCON-EE trial showed 93% healing rate at Week 8 for VOQUEZNA 20mg vs 85% for lansoprazole.","VOQUEZNA demonstrated superiority in moderate-to-severe patients (70% vs 53% at Week 2).","Approval triggers a $175M non-dilutive payment from Revenue Interest Financing Agreement.","VOQUEZNA expected to launch in US in December 2023; marketed exclusively by Phathom."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-268319","json":"https://secwatch.observer/filing/0001193125-23-268319.json","markdown":"https://secwatch.observer/filing/0001193125-23-268319.md","text":"https://secwatch.observer/filing/0001193125-23-268319.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523268319/0001193125-23-268319-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523268319/d579199d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T03:02:16.746072+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}